ALX Oncology Holdings Inc.
ALXO Healthcare Biotechnology
In the quarter to June 2026, EPS grew 73.5%, free cash flow grew 31.7% and total debt fell 3.34%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ALXO
ALX Oncology Holdings Inc. (ALXO) EV/Sales
As of 16 October 2026, ALX Oncology Holdings Inc. (ALXO) trades at a EV/Sales of 8.4×. Over the past ten years it has ranged from −34.2× (March 2025) to 1,169× (September 2021); the current reading is higher than 28% of that period. That is below the Biotechnology industry median of 9.4× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2020 | 478× | 71,560.08% |
| FY2019 | 0.7× | 0.00% |
| FY2018 | 0.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2020 | 478× | 71,560.08% |
| Jun 2020 | 0.7× | 0.00% |
| Mar 2020 | 0.7× | 0.00% |
| Sep 2019 | 0.7× | 0.00% |
| 1 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MSLE Satellos Bioscience Inc. compare | n/m |
| AVXL Anavex Life Sciences Corp. compare | n/m |
| ANTX AN2 Therapeutics, Inc. compare | n/m |
| TLSA Tiziana Life Sciences Ltd compare | n/m |
| CUE Cue Biopharma, Inc. compare | 2.7× |
| ALXO ALX Oncology Holdings Inc. | 5.1× |
| MOLN Molecular Partners AG Sponsored ADR compare | 10.1× |
| KRRO Korro Bio, Inc. compare | 10.5× |
| ABOS Acumen Pharmaceuticals, Inc. compare | 29.3× |
| Biotechnology industry median | 9.4× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)